Clinical Trial

A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-centre, single-arm, open-label, early clinical study to evaluate the safety, tolerability and preliminary efficacy of donor NK cells injection combined with low-dose interleukin-2 in the treatment of acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Protocol Amendment History 4 changes
critical Trial status changed: Unknown → Recruiting 2026-08-06
notable Primary completion pushed: 2025-12-31 -> 2026-12-31 2026-08-06
minor Completion pushed: 2026-06-30 -> 2027-06-30 2026-08-06
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06641648
Lead Sponsor Peking University First Hospital
Conditions Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Relapse, NK Cell
Enrollment 12 participants
Start Date 2025-11-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-05